Healthcare Industry News: Cytogen
News Release - March 16, 2007
Irvine Scientific Launches Their New SIS/AI CatheterSANTA ANA, Calif., March 16 (HSMN NewsFeed) -- Irvine Scientific, a leading medical device/biotechnology company located in Santa Ana, CA, has just announced the launch of their new SIS/AI Catheter. This dual-purpose catheter can be used for both Saline Infusion Sonohysterography (SIS) and Artificial Insemination (AI) or also known as Intrauterine Insemination (IUI). After receiving clearance from the U.S. Food and Drug Administration, this dual-purpose catheter is an alternative outpatient care application that has an ease-of-use to enhance patient comfort.
The design features of the SIS/AI Catheter are optimal for the SIS outpatient procedure because of its smooth and flexible tip, inner lumen, and outer sheath to enhance patient comfort. Other optimal design features include centimeter-depth markings on the inner catheter and outer sheath, and color-coded, flush-bonded hubs to enhance ease-of-use. Certified ISO13485, the rigorous Quality System Standard, the SIS/AI catheter is a sterile, one-time-use catheter. Available in boxes of 10 catheters as catalog number MEAIC18-SIS/AI, this product is available for distribution in the U.S.
"We are pleased to offer this dual-purpose catheter that will continue to support and enhance women's healthcare," stated Dr. Michael Kelly, President and CEO, at Irvine Scientific.
Irvine Scientific, which has provided Reproductive, Prenatal, and Cytogenetics products to the healthcare community for over 25 years, is located in Santa Ana, California and is a subsidiary of Japan Energy Corporation.
For ordering information please visit their website at www.irvinesci.com. For more technical information, please contact Janie Kim, Sr. Product Manager, at email@example.com or at 800-437-5706 x234. For general information about this Press Release, please contact Heather Mills at firstname.lastname@example.org or at 800-437-5706 x215.
Source: Irvine Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.